Citations

Mayo Clinic

Showing 10 of 108551 citations.

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
Fenske, Timothy S. , Ahn, Kwang Woo , Graff, Tara M., Digilio, Alessandro, Kamble, Rammurti T., Ayala, Ernesto , Brammer, Jonathan E. , Cairo, Mitchell S. , Chen, Andy , Chen, Yi‐Bin, D’Souza, Anita , Farooq, Umar , Freytes, Cesar, Ganguly, Siddhartha , Inwards, David J. , Kharfan‐Dabaja, Mohamed A. , Nathan, Sunita , Pawarode, Attaphol , Reddy, Nishitha , Seo, Sachiko , Sureda, Anna , Smith, Sonali M. , Inwards, David, Bashir, Qaiser , Bacher, Ulrike , Chen, Yi‐Bin , Chhabra, Saurabh , Farooq, Umar , Hertzberg, Mark , Jaglowski, Samantha , Lazarus, Hillard M. , Perales, Miguel‐Angel , Hamadani, Mehdi , Chen, Andy I. , D'Souza, Anita

British Journal of Haematology | March 18, 2016 | Volume: 174 | Issue: 2 | Pages: 235-248

10.1111/bjh.14046 | PMID 26989808 Get It

Summary For diffuse large B‐cell lymphoma ( DLBCL ) patients progressing after autologous haematopoietic cell transplantation (auto HCT ), allogeneic HCT (allo HCT ) is often considered, although limited information is available to guide patient selection. Using the Center for International Blood and Marrow Transplant Research ( CIBMTR ) database, we identified 503 patients who underwent allo HCT after disease progression/relapse following a prior auto HCT . The 3‐year probabilities of non‐relapse mortality, progression/relapse, progression‐free survival ( PFS ) and overall survival ( OS ) were 30, 38, 31 and 37% respectively. Factors associated with inferior PFS on multivariate analysis included Karnofsky performance status ( KPS ) <80, chemoresistance, auto HCT to allo HCT interval <1‐year and myeloablative conditioning. Factors associated with worse OS on multivariate analysis included KPS <80, chemoresistance and myeloablative conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS , including KPS <80 (4 points), auto HCT to allo HCT interval <1‐year (2 points) and chemoresistant disease at allo HCT (5 points). This CIBMTR prognostic model classified patients into four groups: low‐risk (0 points), intermediate‐risk (2‐5 points), high‐risk (6‐9 points) or very high‐risk (11 points), predicting 3‐year PFS of 40, 32, 11 and 6%, respectively, with 3‐year OS probabilities of 43, 39, 19 and 11% respectively. In conclusion, the CIBMTR prognostic model identifies a subgroup of DLBCL patients experiencing long‐term survival with allo HCT after a failed prior auto HCT .
Reengineering Dialysis: The Role of Palliative Medicine
Feely, Molly A., Zavaleta, Kathryn W. , Albright, Robert C. , Williams, Amy W. , Swetz, Keith M. , Zavaleta, Kathryn, Thorsteinsdottir, Bjorg

Journal of Palliative Medicine | March 18, 2016 | Volume: 19 | Issue: 6 | Pages: 652-655

10.1089/jpm.2015.0181 | PMID 26991732 Get It

Abstract Background: End-stage renal disease is a life-limiting illness associated with significant morbidity. Half of all individuals with end-stage renal disease are unable to participate in decision making at the end of life, which makes advance care planning critical in this population. Objective: We sought to determine the feasibility of embedding palliative medicine consultations in the hemodialysis unit during treatment runs and the impact of this intervention on advance care planning and symptom management. Design: Single-center, prospective cohort study. Setting/Subjects: Adults receiving in-center hemodialysis at a single outpatient unit were eligible. All consultations occurred during the patients' hemodialysis runs between January 1 and June 30, 2012. Measurement: Medical records were reviewed for documentation of advance directives, resuscitation status, and goals of care discussions before and after palliative medicine intervention. Symptom surveys with the Modified Edmonton Symptom Assessment Scale (validated for end-stage renal disease) were performed preintervention and postintervention. Results: Ninety-two patients were eligible; 91 underwent palliative medicine consultation. Symptoms were well controlled at baseline prior to any intervention. After palliative medicine consultation, the prevalence of unknown code status decreased from 23% to 1% and goals of care documentation improved from 3% to 59%. Conclusion: Palliative medicine consultation during in-center outpatient hemodialysis was well received by patients and clinical staff. Patients' symptoms were well managed at baseline by the primary nephrology team. The frequency of goals of care documentation and clarification of code status improved significantly. Embedded palliative medicine specialists on the dialysis care team may be effective in improving multidisciplinary patient-centered care for patients with end-stage renal disease.
Inadequacy of 3-month Oswestry Disability Index outcome for assessing individual longer-term patient experience after lumbar spine surgery
Asher, Anthony L. , Chotai, Silky , Devin, Clinton J. , Speroff, Theodore, Nian, Hui , Dittus, Robert S., Mummaneni, Praveen V. , Knightly, John J. , Glassman, Steven D. , Bydon, Mohamad , Archer, Kristin R. , Foley, Kevin T. , McGirt, Matthew J., Harrell, Frank E.

Journal of Neurosurgery: Spine | March 18, 2016 | Volume: 25 | Issue: 2 | Pages: 170-180

10.3171/2015.11.spine15872 | PMID 26989974 Get It

OBJECTIVE Prospective longitudinal outcomes registries are at the center of evidence-driven health care reform. Obtaining real-world outcomes data at 12 months can be costly and challenging. In the present study, the authors analyzed whether 3-month outcome measurements sufficiently represent 12-month outcomes for patients with degenerative lumbar disease undergoing surgery. METHODS Data from 3073 patients undergoing elective spine surgery for degenerative lumbar disease were entered into a prospective multicenter registry (N2QOD). Baseline, 3-month, and 12-month follow-up Oswestry Disability Index (ODI) scores were recorded. The absolute differences between actual 12- and 3-month ODI scores was evaluated. Additionally, the authors analyzed the absolute difference between actual 12-month ODI scores and a model-predicted 12-month ODI score (the model used patients' baseline characteristics and actual 3-month scores). The minimal clinically important difference (MCID) for ODI of 12.8 points and the substantial clinical benefit (SCB) for ODI of 18.8 points were used based on the previously published values. The concordance rate of achieving MCID and SCB for ODI at 3-and 12-months was computed. RESULTS The 3-month ODI scores differed from 12-month scores by an absolute difference of 11.9 ± 10.8, and predictive modeling estimations of 12-month ODI scores differed from actual 12-month scores by a mean (± SD) of 10.7 ± 9.0 points (p = 0.001). Sixty-four percent of patients (n = 1982) achieved an MCID for ODI at 3 months in comparison with 67% of patients (n = 2088) by 12 months; 51% (n = 1731) and 61% (n = 1860) of patients achieved SCB for ODI at 3 months and 12 months, respectively. Almost 20% of patients had ODI scores that varied at least 20 points (the point span of an ODI functional category) between actual 3- and 12-month values. In the aggregate analysis of achieving MCID, 77% of patients were concordant and 23% were discordant in achieving or not achieving MCID at 3 and 12 months. The discordance rates of achieving or not achieving MCID for ODI were in the range of 19% to 27% for all diagnoses and treatments (decompression with and without fusion). The positive and negative predictive value of 3-months ODI to predict 12-month ODI was 86% and 60% for MCID and 82% and 67% for SCB. CONCLUSIONS Based on their findings, the authors conclude the following: 1) Predictive methods for functional outcome based on early patient experience (i.e., baseline and/or 3-month data) should be used to help evaluate the effectiveness of procedures in patient populations, rather than serving as a proxy for long-term individual patient experience. 2) Prospective longitudinal registries need to span at least 12 months to determine the effectiveness of spine care at the individual patient and practitioner level.
Drug–resin drug interactions in patients with delayed gastric emptying: What is optimal time window for drug administration?
Camilleri, Michael

Neurogastroenterology & Motility | March 18, 2016 | Volume: 28 | Issue: 8 | Pages: 1268-1271

10.1111/nmo.12823 | PMID 26987693 Get It

AbstractMost drug–drug interactions involve overlap or competition in drug metabolic pathways. However, there are medications, typically resins, whose function is to bind injurious substances such as bile acids or potassium within the digestive tract. The objective of this article is to review the functions of the stomach and the kinetics of emptying of different food forms or formulations to make recommendations on timing of medication administration in order to avoid intragastric drug interactions. Based on the profiles and kinetics of emptying of liquid nutrients and homogenized solids, a window of 3 h between administration of a resin drug and another ‘target’ medication would be expected to allow a median of 80% of medications with particle size <1 mm to empty from the stomach and, hence, avoid potential interaction such as binding of the ‘target’ medication within the stomach.
Organization and Practice in Tuberculosis Bacteriology
Roberts, Glenn D.

American Journal of Clinical Pathology | March 18, 2016 | Volume: 87 | Issue: 4 | Pages: 554-554

10.1093/ajcp/87.4.554a Get It

Malignant Peripheral Nerve Sheath Tumor: An Immunohistochemical Study of 62 Cases
Scheithauer, Bernd W., Manivel, J. Carlos , Wick, Mark R. , Swanson, Paul E

American Journal of Clinical Pathology | March 18, 2016 | Volume: 87 | Issue: 4 | Pages: 425-433

10.1093/ajcp/87.4.425 | PMID 2435144 Get It

Type 2 Diabetes Mellitus Trajectories and Associated Risks
Oh, Won-Suk , Kim, Era, Castro, M. Regina , Kumar, Vipin , Steinbach, Michael , Simon, György , Caraballo, Pedro J. , Simon, Gyorgy J, Oh, Wonsuk

Big Data | March 18, 2016 | Volume: 4 | Issue: 1 | Pages: 25-30

10.1089/big.2015.0029 | PMID 27158565 Get It

The Antimicrobial Removal Device: A Microbiological and Clinical Evaluation
Wright, Alan J. , Thompson, Rodney L., McLimans, C A, Wilson, Walter R. , Washington, John A.

American Journal of Clinical Pathology | March 18, 2016 | Volume: 78 | Issue: 2 | Pages: 173-177

10.1093/ajcp/78.2.173 | PMID 7048940 Get It

Cutaneous Lymphomas: Correlation of Histochemical and Immunohistochemical Characteristics and Clinicopathologic Features
Krishnan, Jayashree , Li, Chin-Yang, Su, W. P. Daniel

American Journal of Clinical Pathology | March 18, 2016 | Volume: 79 | Issue: 2 | Pages: 157-165

10.1093/ajcp/79.2.157 | PMID 6600578 Get It

Immunocytochemical Characterization of Human Blood Cells
Yam, Lung T., English, Mary C., Janckila, Anthony J., Ziesmer, Steve, Li, Chin‐Yang

American Journal of Clinical Pathology | March 18, 2016 | Volume: 80 | Issue: 3 | Pages: 314-321

10.1093/ajcp/80.3.314 | PMID 6192705 Get It